Tag: Pharnext
Pharnext: receives two offers of more than 250 ME – 10/16/2023 at 09:45
(CercleFinance.com) – Pharnext announces that it has received two binding offers with a view to signing an agreement to develop ‘PXT3003’, its most advanced drug candidate currently in a pivotal…
Pharnext jumps after receiving 2 offers for its candidate against Charcot disease – 10/16/2023 at 10:06
(AOF) – Pharnext (+111% to 0.24 euros) jumps after announcing today that it has received two binding offers with a view to signing an agreement to promote PXT3003, its most…
Pharnext: Receives two offers of more than 250 ME
(CercleFinance.com) – Pharnext announces that it has received two binding offers with a view to signing an agreement to develop ‘PXT3003’, its most advanced drug candidate currently in a pivotal…
PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the par value of the shares – 10/10/2023 at 6:00 p.m.
PARIS, France, October 10, 2023 at 6 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative…
PHARNEXT: Adjustment of the nominal value – 09/29/2023 at 7:00 p.m.
PARIS, France, September 29, 2023 at 7 p.m. (CET) – Pharnext SA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext again raises 800,000 euros through Oceane-BSA issuance – 09/26/2023 at 6:21 p.m.
(AOF) – Pharnext announces a fundraising of 800,000 euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. The biotech developing new therapies for neurodegenerative diseases without satisfactory…
Pharnext again raises 800,000 euros through Oceane-BSA issue
(AOF) – Pharnext announces a fundraising of 800,000 euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. The biotech developing new therapies for neurodegenerative diseases without satisfactory…
Pharnext: the stock falls again after a fundraising – 09/22/2023 at 12:35
(CercleFinance.com) – Pharnext announced on Friday that it had completed a fundraising of 1.3 million euros via the issue of Océanes-BSA subscribed by Global Tech Opportunities 13. The biopharmaceutical company…
Pharnext enters the home stretch to sign a licensing agreement for its drug candidate for Charcot disease
(Boursier.com) — Pharnext SCA, an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without a satisfactory therapeutic solution, today announces that it is entering the home stretch…
PHARNEXT: Fundraising of 1.3 million euros – 09/21/2023 at 8:30 p.m.
PARIS, France, September 21, 2023 at 8:30 p.m. (CET) – Pharnext SCA (FR001400GUN7 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext: Expressions of interest received, the title soars
(CercleFinance.com) – The biopharmaceutical company Pharnext is trading on the Paris Stock Exchange this Wednesday after receiving several expressions of interest with a view to signing a possible licensing agreement.…
PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the nominal value of the shares – 09/06/2023 at 6:00 p.m.
PARIS, France, SEPTEMBER 6, 2023 at 6 p.m. (CET) – Pharnext SCA (FR001400GUN7 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative…